NCT05152966View on ClinicalTrials.gov

Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
Persistent Atrial Fibrillation
Interventions
DEVICE

Ablation

Ablation using the FARAPULSE™ Cardiac Ablation System Plus

Trial Locations (1)

Unknown

Nemocnice Na Homolce, Prague

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT05152966 - Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II) | Biotech Hunter | Biotech Hunter